Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

118 results about "Sublingual administration" patented technology

Sublingual (abbreviated SL), from the Latin for "under the tongue", refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue. Many drugs are designed for sublingual administration, including cardiovascular drugs, steroids, barbiturates, benzodiazepines, opioid analgesics, enzymes and, increasingly, vitamins and minerals.

Fentanyl composition for the treatment of acute pain

A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and / or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
Owner:DIABAKT AB

Rapid acting drug delivery compositions

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.
Owner:ELI LILLY & CO

Rapid acting drug delivery compositions

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.
Owner:ELI LILLY & CO

Fast-disintegrating epinephrine tablets for buccal or sublingual administration

InactiveUS20070202163A1BiocideOrganic active ingredientsPlasma epinephrineInjection epinephrine
Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations substantially equivalent to those achieved by traditional injectable dosage forms comprising epinephrine injected either subcutaneously or intramuscularly.
Owner:UNIVERSITY OF MANITOBA

Fast-disintegrating epinephrine tablets for buccal or sublingual administration

InactiveUS20070059361A1Organic active ingredientsBiocidePlasma epinephrineSublingual administration
Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen).
Owner:UNIVERSITY OF MANITOBA

Rapid Acting Drug Delivery Compositions

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.
Owner:BIODEL INC

Solid dosage form composition for buccal or sublingual administration of cannabinoids

The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same.
Owner:AVENTIS PHARMACETICAL PRODUCTS INC

Rapid mucosal gel or film insulin compositions

Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. Following administration, these formulations are rapidly absorbed into the blood stream. The formulation is preferably a polymeric gel, powder or film which adheres to the mucosal surface, thereby enhancing uptake of the incorporated drug. In the preferred embodiment, this formulation is administered sublingually, most preferably before a meal or after a meal.
Owner:BIODEL INC

Sublingual administration of dihydroergotamine for the treatment of migraine

The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine sublingually, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.
Owner:ALAMO PHARMA

Pharmaceutical composition based on agonist of benzodiazepine

InactiveUS20060134200A1Act quicklyBiocideNervous disorderCelluloseBromazepam
The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at least, 70% of the weight of the final formulation containing 40-45% by weight of lactose, 15-27% by weight of sorbitol and 12-16% by weight of cellulose.
Owner:SIGMA PHARMA LTDA

Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.
Owner:SCIELE PHARMA

Rapid Mucosal Gel or Film Insulin Compositions

Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. Following administration, these formulations are rapidly absorbed into the blood stream. The formulation is preferably a polymeric gel, powder or film which adheres to the mucosal surface, thereby enhancing uptake of the incorporated drug. In the preferred embodiment, this formulation is administered sublingually, most preferably before a meal or after a meal.
Owner:BIODEL

Methods and Systems for Sublingual Guarana Administration

Embodiments of the present invention relate generally to methods and systems for the sublingual and buccal administration of herbal supplements, and more particularly, to the sublingual and buccal administration of Guaraná, which allows for considerably reducing the therapeutic dose, with the additional advantage of increasing the quickness of the beneficial effects.
Owner:NELSON BRET D

Sublingual spray for the treatment of pain

InactiveUS20090117054A1Improve solubilityBiocideNervous disorderTreatment painPain controlling
This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies.
Owner:UNIV OF KENTUCKY RES FOUND

Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt

The invention relates to a formula of a sartan compound or a pharmaceutically acceptable salt thereof and a calcium channel blocker or a pharmaceutically acceptable salt, which belong to the technical field of medicine. The formula comprises the following components by weight proportion: 5-200 parts of [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and a carboxylic acid compound and salt thereof and 0.5-60 parts of a calcium ion retarder; the preferable scheme is 20-100 parts of the [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and the carboxylic acid compound and the salt thereof and 1-30 parts of the calcium ion retarder; the administration forms can be one of the following forms such as oral administration, inhalation, subcutaneous administration, sublingual administration, intramuscular administration, intravenous administration, transdermal administration, local administration or rectal administration. In the formula of the invention, an antihypertensive I and the calcium channel blocker or the pharmaceutically acceptable salt are studied; thus a preparation with a new formula for treating hypertension is provided. The preparation is characterized by low dosage, obvious blood pressure lowering effect and little adverse reaction.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY

Buccal and sublingual administration of physostigmine

InactiveUS6264974B1Prolonged stable blood levelBiocidePowder deliveryPh controlAdditive ingredient
Physostigmine, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5ol methylcarbamate, administered buccally or sublingually in non-sustained release dosage form provides extremely prolonged blood levels. This active agent is physically compounded with materials of some or all of classes of ingredients that function as pH controls, preservative agents, viscosity control agents, absorption enhancers, stabilizing agents, solvents, and carrier vehicles. This compounding will produce a pharmaceutical composition in the form of a liquid, tablet, gel, patch or lozenge for administration of the active agent, Physostigmine, by absorption through the buccal or sublingual mucosa of the patient. This method of delivery of Physostigmine and similar compounds is useful for treatment of cognitive deficiencies and / or neurological function deficits, mood and / or mental disturbances in mammals including human beings.
Owner:MADHAT MAHER N

Method for testing and treating delayed food allergies

A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentration for sublingual administration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance.
Owner:SHEA JOHN

Verifiable absorption drug delivery form based on cyclodextrins

Solid dosage forms are produced by absorbing solutions of drug:cyclodextrin inclusion complexes on absorbing matrices and then drying. The matrices may, but need not, disintegrate in water. The resulting forms are suitable for oral or sublingual administration, and also can be used in topical administrations to mucosa covered tissues. They are particularly suitable for sublingual administration because the eluted, nondisintegrated matrix (e.g., absorbing paper) can be recovered and checked for completion of elution. This enables documentation that effective absorption occurred from the mouth cavity.
Owner:PITHA JOSEF

Agomelatine-containing medicinal composition for oral mucosa or sublingual administration

The invention discloses an agomelatine-containing medicinal composition for oral mucosa or sublingual administration and a preparation method thereof. The medicinal composition consists of a main medicament of which the particle diameter is 48-250 mum and is preferably 48-150 mum, and medicinal auxiliary materials. The medicinal composition can be prepared through a simple preparation process without special production equipment, has low manufacturing cost, and is suitable industrial production; moreover, the use compliance of a patient is improved through the excitement of the taken medicament in an oral cavity; and the medicinal composition is absorbed directly through oral mucosa, so that the first pass effect of the conventional oral medicament is avoided, and the bioavailability is high.
Owner:CHENGDU KANGHONG PHARMA GRP

Edaravone and (+)-2-camphol sublingual medicine composition

The invention discloses an edaravone and (+)-2-camphol composition sublingual medication preparation and a preparation method thereof, wherein the sublingual medication preparation is prepared from edaravone, (+)-2-camphol, excipients, filling agents, bonding agents, disintegrating agents, lubricating agents and the like. The sublingual medication preparation has the advantages that the first passeffect of the liver can be avoided; the sample stability is high; the transportation is convenient; the use is convenient, and the like.
Owner:YANTAI YENEPHARMA BIOMEDICAL

Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.
Owner:SCIELE PHARMA

New usages of lotus plumule and alkaloid thereof and derivative thereof

The invention provides new usages of lotus plumule and alkaloid thereof and derivative thereof, such as lotus total alkaloids, liensinine, isoliensinine and methyl liensinine, in particular to the usages of lotus plumule and extract thereof, lotus plumule total alkaoids, bis-benzyl-isoquinoline alkaloid derivative or analogue in preparing drugs for curing senile dementia or healthcare food or food additives. The new usages are characterized in that the lotus plumule and extract thereof, the lotus plumule total alkaoids, the bis-benzyl-isoquinoline alkaloid derivative or the analogue are adopted as main active ingredients, and other compatible active ingredients are combined to form a new formula to prevent and treat dementia (including senile dementia and vascular dementia), improve learning and memory and the like. The dosage forms can be solid forms, liquid forms and the like used for different administrations such as oral taking, sublingual administration, nasal mucosa administration, percutaneous administration, muscle administration, vein administration and rectum administration.
Owner:李宏

Ginkgo flavone and lactone dispersion tablet and preparation method thereof

The invention relates to a gingko ketonic ester dispersible tablet and its preparation method, and belongs to the field of Chinese traditional medicine. The tablet mainly comprises gingko ketonic ester and proper adjuvant. The inventive preparation has effects in activating blood circulation, dispelling blood stasis, and dredging meridians. The inventive dispersible tablet has improved water solubility and can rapidly disinregrate in cold water and form uniform suspensoid liquid. It has various administration manner including direct drink, direct deglutition, sublingual administration. It has convenient administration, high bioavailability, good taste, easy acceptability, rational and feasible technology, and stable and controllable quality.
Owner:BEIJING YINKERUISI BIOLOGICAL PODUCTS RES INST

Use of sublingual dexmedetomidine for the treatment of agitation

The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and / or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
Owner:BIOXCEL THERAPEUTICS INC +1

Use of sublingual dexmedetomidine for the treatment of agitation

The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and / or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
Owner:BIOXCEL THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products